NASDAQ$EDIT
Editas Medicine Inc · Q4 2021 earnings
Q4 2021 earnings · · Investor relations
Briefing
Editas Medicine reported a net loss and increased collaboration revenue for Q4 2021.
Editas Medicine reported a net loss of $41.4 million for the fourth quarter of 2021, with collaboration and other research and development revenues increasing to $12.5 million. The company's cash, cash equivalents, and marketable securities totaled $619.9 million as of December 31, 2021, expected to fund operations through 2023.
- EDIT-101 Phase 1/2 BRILLIANCE trial enrolling mid-dose pediatric cohort; clinical data update expected in 2H 2022
- EDIT-301 remains on track to dose first sickle cell disease patient in 1H 2022 and first TDT patient in 2022
- EDIT-103 for RHO-adRP and EDIT-202 for solid tumors advancing towards IND-enabling studies
- First ever in vivo ocular gene editing data demonstrated evidence of gene editing and potential clinical benefit; clinical update expected in 2H 2022
Headline financials
Revenue & EPS history
Editas · Revenue · Quarterly
$12.5M
Revenue by segment
Editas · $5.34M total across 1 segment · Q3 2023
- Collaboration & R&D$5.34M+12604.8%100.0%
Forward guidance
Editas Medicine anticipates several milestones in 2022, including clinical data updates for EDIT-101 and EDIT-301, the start of patient dosing in the beta thalassemia trial, and the beginning of IND-enabling studies for EDIT-202.
Tailwinds
- Completing dosing of the pediatric mid-dose cohort in the first half of 2022
- Initiating dosing of the pediatric high-dose cohort in the BRILLIANCE trial in 2022
- Establishing registrational trial criteria by year-end 2022
- Dosing the first patient in the RUBY trial in the first half of 2022
- Dosing the first TDT patient with EDIT-301 in 2022
Headwinds
- Uncertainties inherent in the initiation and completion of pre-clinical studies and clinical trials
- Availability and timing of results from pre-clinical studies and clinical trials
- Whether interim results from a clinical trial will be predictive of the final results of the trial or the results of future trials
- Expectations for regulatory approvals to conduct trials or to market products
- Availability of funding sufficient for the Company’s foreseeable and unforeseeable operating expenses and capital expenditure requirements
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2021
+4.5%
Avg return
Earnings day
+4.4%
Avg return
5 days after
+2.0%
Avg return
30 days after
71%
29 / 41 earnings
Positive
+29.4%
Q2 2021
Best reaction
-11.8%
Q4 2020
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +1.3% | +3.7% | -0.7% | |
| Q4 2025 | +15.5% | +22.0% | +38.0% | |
| Q3 2025 | +1.4% | +5.3% | +5.3% | |
| Q1 2025 | -2.7% | -1.9% | +41.6% | |
| Q4 2024 | +16.5% | -11.4% | -41.5% | |
| Q3 2024 | +7.2% | +7.2% | -31.6% | |
| Q2 2024 | -10.0% | -16.2% | -23.3% | |
| Q1 2024 | -2.1% | +0.5% | -6.7% | |
| Q4 2023 | +13.5% | +12.0% | -16.3% | |
| Q3 2023 | +18.2% | +19.5% | +53.2% | |
| Q2 2023 | +7.6% | -2.5% | +5.0% | |
| Q1 2023 | +10.3% | +14.6% | +10.9% | |
| Q4 2022 | +2.3% | -1.5% | -18.7% | |
| Q3 2022 | -8.5% | -13.4% | -19.6% | |
| Q2 2022 | +16.2% | +16.1% | -10.0% | |
| Q1 2022 | +2.7% | -21.7% | -16.0% | |
| Q4 2021 | +17.3% | +21.4% | +30.2% | |
| Q3 2021 | +8.2% | +1.1% | -14.9% | |
| Q2 2021 | +29.4% | +37.9% | +62.1% | |
| Q1 2021 | -0.9% | -9.7% | -2.9% | |
| Q4 2020 | -11.8% | -8.1% | -18.6% | |
| Q3 2020 | +0.1% | -1.9% | +13.3% | |
| Q2 2020 | +6.8% | +5.2% | -6.2% | |
| Q1 2020 | -1.2% | +1.9% | +6.6% | |
| Q4 2019 | -6.7% | +1.1% | -11.2% | |
| Q3 2019 | +12.8% | +12.1% | +47.8% | |
| Q2 2019 | +2.4% | +3.8% | +1.1% | |
| Q1 2019 | -2.8% | -5.5% | -20.4% | |
| Q4 2018 | +12.8% | +12.8% | +16.7% | |
| Q3 2018 | +10.7% | +4.1% | +4.8% | |
| Q2 2018 | +0.5% | +3.3% | +11.6% | |
| Q1 2018 | +1.0% | +2.4% | +13.2% | |
| Q4 2017 | +9.9% | +14.6% | -14.5% | |
| Q3 2017 | -6.9% | +1.5% | +7.3% | |
| Q2 2017 | +4.6% | +22.8% | +6.5% | |
| Q1 2017 | -5.1% | -7.2% | -17.1% | |
| Q4 2016 | +4.4% | +19.2% | +0.8% | |
| Q3 2016 | +5.1% | +23.6% | +19.4% | |
| Q2 2016 | -9.3% | -15.1% | -27.4% | |
| Q1 2016 | +7.0% | — | — | |
| Q4 2015 | +5.9% | — | — | |
| Q3 2015 | — | — | — | |
| Q2 2015 | — | — | — | |
| Q1 2015 | — | — | — | |
| Q4 2014 | — | — | — | |
| Q3 2014 | — | — | — | |
| Q2 2014 | — | — | — | |
| Q1 2014 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro